TARO-FINGOLIMOD 0.5 MG
FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) : 0.5 MG · DIN 02469618 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-FINGOLIMOD?
TARO-FINGOLIMOD 0.5 MG contains FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02469618, held by TARO PHARMACEUTICALS INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02469618 |
|---|---|
| Brand name | TARO-FINGOLIMOD |
| Generic / active ingredient | FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) : 0.5 MG |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 0.5 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AE01 FINGOLIMOD |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Oct-2019 |
What can be used instead?
Other Canadian products sharing ATC code L04AE01 FINGOLIMOD. 8 of 12 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-FINGOLIMOD | 0.5 MG | CAPSULE | ACCORD HEALTHCARE INC | MARKETED | DIN 02475669 |
| GILENYA | 0.25 MG | CAPSULE | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02482533 |
| GILENYA | 0.5 MG | CAPSULE | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 02365480 |
| JAMP FINGOLIMOD | 0.5 MG | CAPSULE | JAMP PHARMA CORPORATION | MARKETED | DIN 02487772 |
| MYLAN-FINGOLIMOD | 0.5 MG | CAPSULE | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02469715 |
| PMS-FINGOLIMOD | 0.5 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02469782 |
| SANDOZ FINGOLIMOD | 0.5 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02482606 |
| APO-FINGOLIMOD | 0.5 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02469936 |
| ASN-FINGOLIMOD | 0.5 MG | CAPSULE | ASCEND LABORATORIES LTD | APPROVED | DIN 02500914 |
| MAR-FINGOLIMOD | 0.5 MG | CAPSULE | MARCAN PHARMACEUTICALS INC | DORMANT | DIN 02474743 |
Who else supplies FINGOLIMOD worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FINGOLIMOD appears in 212 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.